Pharmacy personnel should always wear impervious gloves when handling bottles of Hydrea (hydroxyurea) to minimize skin exposure to the antineoplastic agent, according to its manufacturer Bristol-Myers Squibb. Other changes to the Hydrea labeling include warnings about incidents of cutaneous vasculitic toxicities among myeloproliferative disorder patients and that renal functioning should be checked among elderly patients, who may also need lower doses. For questions about Hydrea or to report suspected adverse events, phone 1-(800) 321-1335.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.